Marvel Biosciences Corp
XTSX:MRVL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Marvel Biosciences Corp
Operating Income
Marvel Biosciences Corp
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Marvel Biosciences Corp
XTSX:MRVL
|
Operating Income
-CA$1.5m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-174%
|
CAGR 10-Years
N/A
|
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Operating Income
-$217.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Operating Income
-CA$13.9m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-96%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Operating Income
$106.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Operating Income
-$151.2m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
-123%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Operating Income
-CA$36.8m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-73%
|
CAGR 10-Years
N/A
|
|
Marvel Biosciences Corp
Glance View
Marvel Biosciences Corp. operates as a biotechnology company that utilizes a drug redevelopment approach to drug development. The company is headquartered in Calgary, Alberta. The company went IPO on 2019-02-28. The firm is focused on the discovery of new chemical entities that inhibit the A2a adenosine receptor. The firm has developed several new chemical entities, using synthetic chemical derivatives of known drugs, that inhibit the A2a adenosine receptor with application to neurological diseases, including depression and anxiety, Alzheimer’s, attention deficit hyperactivity disorder (ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The firm is focused on the development of its lead molecule, MB-204 (Target 1b), which is in Phase I clinical trials. Its wholly owned subsidiary is Marvel Biotechnology Inc.
See Also
What is Marvel Biosciences Corp's Operating Income?
Operating Income
-1.5m
CAD
Based on the financial report for Jul 31, 2025, Marvel Biosciences Corp's Operating Income amounts to -1.5m CAD.
What is Marvel Biosciences Corp's Operating Income growth rate?
Operating Income CAGR 5Y
-174%
Over the last year, the Operating Income growth was -22%. The average annual Operating Income growth rates for Marvel Biosciences Corp have been 15% over the past three years , -174% over the past five years .
